Leerink Partners Initiates Coverage On Obsidian Therapeutics with Outperform Rating, Announces Price Target of $32

Leerink Partners has initiated coverage on Obsidian Therapeutics (NASDAQ: OBX) with an Outperform rating. The firm has set a price target of $32 for the company's stock.